

# Dehydroepiandrosterone Sulphate and Corticotropin Levels Are High in Young Male Patients with Conduct Disorder: Comparisons for Growth Factors, Thyroid and Gonadal Hormones

T.N. Dmitrieva<sup>a,c</sup> R.D. Oades<sup>a</sup> B.P. Hauffa<sup>b</sup> C. Eggers<sup>a</sup>

<sup>a</sup>Clinic for Child and Adolescent Psychiatry and Psychotherapy, <sup>b</sup>Department of Paediatric Haematology, Oncology and Endocrinology, Children's Hospital, University of Essen, Germany; <sup>c</sup>Clinic for Psychiatry N1, Nizhny Novgorod, Russia

## Key Words

Conduct disorder · Dehydroepiandrosterone sulphate · Corticotropin · Testosterone · Thyroid · Neurodevelopment · Insulin-like growth factor I

## Abstract

Childhood conduct disorder (CD) may originate in a stressful upbringing, and be associated with unusual physical or sexual development and thyroid dysfunction. We therefore explored circulating levels of hormones from adrenal, gonadal and growth hormone axes associated with stress, aggression and development in 28 CD patients and 13 age-matched healthy children (10–18 years old). The CD group had higher levels of dehydroepiandrosterone sulphate (DHEA-S), corticotropin (ACTH) and free tri-iodothyronine (fT<sub>3</sub>) if under 14 years. There were no differences for gonadal hormones or maturity ratings which were not associated with aggression. Smaller physical measures in CD children correlated with DHEA-S and growth factors (e.g. insulin-like growth factor I) increased ACTH and fT<sub>3</sub> correlated with

restless-impulsive ratings, and DHEA-S with 'disruptive behaviour'. Imbalances in the adrenal and growth axes may have neurotropic repercussions in development.

Copyright © 2001 S. Karger AG, Basel

## Introduction

Childhood conduct (CD) and oppositional disorders are marked by impulsive verbal and non-verbal aggression [1]. The prevalence and outcome of CD is illustrated by a study of 6,500 males born in Stockholm in 1953; 7.2% had CD problems and 76% of these had a criminal record and/or mental disorder by the age of 30 years [2]. CD predicts the development of personality disorders [3], delinquency and substance abuse [4] and has been related to a dysfunctional family life, low socio-economic status and parental psychopathology [5]. But little attention has been given to endocrinological correlates strongly linked to neural and behavioural development.

Hence, we made an exploratory analysis of the function of four hormonal axes associated with stress and

**Table 1.** Data for healthy CON and CD subjects

	CON (13)		CD (28)			
	mean	SD	mean	SD		
Age, years	13.9	1.5	10.7–16.8	13.2	1.9	10.0–17.8
<i>Conners Scale</i>						
Restlessness	0.31	0.48		1.92	0.85 <sup>b</sup>	
Impulsivity	0.38	0.51		2.31	0.84 <sup>b</sup>	
Disturbs others	0.23	0.44		1.69	1.0 <sup>b</sup>	
Attention span	0.62	0.65		1.69	1.0 <sup>a</sup>	
Fidgetiness	0.08	0.28		1.38	1.06 <sup>a</sup>	
Distractibility	0.62	1.0		1.69	0.93 <sup>a</sup>	
Easily frustrated	0.46	0.66		1.92	1.09 <sup>a</sup>	
Easily cry	0.08	0.28		0.96	0.82 <sup>a</sup>	
Emotional lability	0.38	0.51		1.69	0.93 <sup>a</sup>	
Aggressive	0.31	0.63		1.85	1.21 <sup>b</sup>	
SUM	3.5	3.3		17.0	5.5 <sup>b</sup>	
<i>Stature, cm</i>						
Height	168.1	21.7		161.0	14.5	
Chest	85.4	13.5		81.6	10.8	
Legs	90.9	9.1		85.2	8.2 <sup>a</sup>	
Shoulder	40.9	6.5		36.2	3.8 <sup>a</sup>	
Bitrochanter	34.0	7.1		28.4	3.7 <sup>a</sup>	
<i>Sexual maturity, n (%)</i>						
Normal	7	54		21	75	
Advanced	4	31		6	21	
Delayed	2	15		1	4	

CON vs. CD: <sup>a</sup>F (1, 37) = 10.7–14.0, p < 0.002; <sup>b</sup>F (1, 37) = 18.9–57.5, p < 0.0001; <sup>c</sup>F (1, 35) = 4.6, p < 0.04; <sup>d</sup>F (1, 35) = 7.5–10.3, p < 0.01, with age as covariate. Student's t tests confirmed the probability levels to within 1%.


development (pituitary-adrenal, gonadal, thyroid and growth) in normal children and those with CD. Pituitary-adrenal function (corticotropin, ACTH; cortisol, CS; dehydroepiandrosterone sulphate, DHEA-S) was studied because of the potential association of stress with the origin of the condition, evidence for disturbed feedback control of pituitary hormones in childhood psychiatric conditions [6] and conflicting reports of CS differences in some CD subgroups [7, 8]. Androgens (testosterone, Te; DHEA-S) and oestradiol (E<sub>2</sub>) were selected in view of reported associations of serum Te levels with aggression in children and adults [9, 10], and the potential for a contribution of delayed/advanced maturation in related conditions [11]. Thyroid function (thyroid-stimulating hormone, TSH, free tri-iodothyronine, fT<sub>3</sub>, and free thyroxine, fT<sub>4</sub>) and growth factors (insulin-like growth factor I, IGF-I; insulin-like-growth-factor-binding protein 3, IGFBP-3), are associated with development and maturation. While thyroid resistance may [12] or may not be pertinent for CD or related disorders [13], short stature and

delayed puberty may in some cases relate to unusual thyroid function [12] and to psychiatric features of personality development [14, 15].

## Methods

### Subjects

Subjects were 41 young male children and adolescents (10–18 years old). Diagnoses of consecutive referrals to the university clinic for child and adolescent psychiatry were made by 2 clinicians (ICD-10) based on a review of the patient history, behavioural observation during routine psychological testing, the short Conners parent-teacher rating scale (CPTQ [16]) and the child behaviour checklist (CBCL [17]). Externalising and internalising behaviour ratings were derived from the CPTQ and CBCL. The study group consisted of 28 CD patients free of medication: 19 had CD alone (F91.x), 6 had comorbid emotional (F92.8 and F92.9) and 3 had comorbid ADHD (F90.1). The comparison group consisted of 13 healthy subjects (CON) without medical problems who reported to a general practitioner for a routine check and were age-matched with the patients. All subjects presented for a physical examination, ratings of sexual maturity and a blood sample (table 1). Exclusion criteria were other



**Fig. 1.** **a** Levels of circulating corticotropin and steroid hormones. **b** Levels of growth factors and hormones of the thyroid axis in healthy control (CON) and conduct-disordered children (CD). \*  $p < 0.05$ ; \*\*  $p < 0.01$ .

major medical illness or psychiatric/psychologic consultation. After obtaining approval from the clinic for the research, examination followed the consent of the child, the responsible adult and the therapist.

The Tanner scale for sexual maturation rates the degree of secondary hair growth, appearance of the scrotum and penis growth in 5 stages [18]. Maturity was classified as delayed or advanced if the ratings differed from the age norm by more than one stage. For all controls, ratings matched the norms for chronological age to within 12 months. No value exceeded 4 on this scale. Anthropometric measures included height, weight, chest circumference, leg length, shoulder breadth and the inter-trochanteric distance. Height was measured with a Harpenden stadiometer, and other measures were obtained with calibrated clinical scales and a tape measure. These measures were compared with the percentile ranges of a normal middle-European population [19].

#### Blood Sample Analysis

Two blood samples were taken between 8.30 and 9.30 a.m. The first was collected in EDTA tubes and placed immediately on ice. Plasma was separated from blood cells within 3 h and used to measure ACTH. Serum from the second sample was used to measure the other hormones. Samples were stored at  $-20^{\circ}\text{C}$  until analysis. The analysis used commercially available specific radioimmunoassay kits suitable for a paediatric endocrine laboratory without prior separation steps. The source, sensitivity and the intra-/interassay variabilities (CV%) over the assay range were: ACTH (Nichols) 1 pg/ml, 5.4–5.8%, 3.2–4.9%; CS (Cortisol Bridge™, Serono) 1.9 ng/ml, 2.8–4.8%, 2.2–9.3%; DHEA-S (Sorin) 0.5 ng/ml, 4.3–4.8%, 8.9–9.4%; Te (Diagnostic Products) 6 ng/dl, 5.6–7.2%, 6.6–7.1%; E<sub>2</sub> (Sorin) 5.2 pg/ml, 5.8–7.1%, 7.2–8.9%; LH (MAIAclone™, Serono) 0.15 IU/l, 2.0–4.7%, 2.0–6.1%; FSH (MAIAclone™, Serono) 0.25 IU/l, 1.1–2.5%, 2.5–4.3%; PRL (MAIAclone™, Serono) 6.0 mIU/ml, 2.3–3.2%, 2.5–2.8%; TSH (IRMAclone™, Henning) 0.09  $\mu\text{U/ml}$ , 1.2–6.2%, 2.4–9.2%; FT<sub>3</sub> (Brahms) 0.47 pg/ml, 2.8–4.2%, 3.2–6.3%; FT<sub>4</sub>

(DYNOTest™, Henning) 0.1 ng/dl, 2.1–6.7%, 8.2–9.0%; IGF-I (IGFBP blocked, Biomérieux) 0.02 ng/ml, 2.8–3.9%, 5.4–7.5%; IGFBP-3 (Biomérieux) 0.06 ng/ml, 4.8–9.68%, 9.5–14.1%.


#### Data Treatment

Data from the Conners scale and the physical examination were examined by analysis of variance and the Student *t* test. As data for only 2 subjects were in part missing, and the variance of the data for 39 subjects was homogeneous, the effect of age was examined by a parametric analysis of covariance that confirmed the group differences. A mistake in sample taking led to some missing hormone measures in up to 3 CD and 5 CON subjects. Thus, this exploratory analysis of relatively small and uneven subject samples used non-parametric Mann-Whitney *U* tests. Spearman's rank correlations are provided with a view to generating working hypotheses with trends cited as  $p > 0.01$  and significant correlations as  $p < 0.01$ . As a check on developmental changes, groups of CON and CD subjects younger and older than the control mean were also studied.

## Results

### Behaviour, Stature and Maturity

Conners scores were higher for the CD than the CON group on each item [ $F(10, 28) = 7.3, p < 0.0001$ ; table 1], especially for restlessness, impulsivity, fidgetiness, ease of frustration, disturbance of others and aggression. Externalising and internalising problems (CBCL) were evenly distributed (scores were higher for internalising in 6, externalising in 9 and equivalent in 13 patients). Physical differences between the groups remained after covarying for age [ $F(5, 31) = 6.0, p < 0.0006$ ]. The CD group had



**Fig. 2.** **a** Spearman's correlations for DHEA-S with chronological age (top) and chest measurements (bottom) are compared for CD (○: significant) and CON children (●: nonsignificant). **b** Spearman's correlations for DHEA-S with the symptom 'disturbs others' (top), and ACTH with the sum of Conners symptom ratings (bottom) + SD.

less broad shoulders, a smaller bitrochanter distance and shorter legs (table 1). There were no differences in the degree of sexual maturation.

#### Hormone Levels: Group Comparisons

There were no group differences for gonadal steroids and gonadotropins (fig. 1a). However, among the pituitary-adrenal hormones, DHEA-S showed a 50% increase ( $U = 109$ ,  $z = -2.05$ ,  $p = 0.04$ ) and ACTH a fourfold increase in the CD group ( $U = 17$ ,  $z = -4.14$ ,  $p < 0.0001$ ). There were no differences for CS (fig. 1a) or the thyroid hormones  $fT_4$  and TSH, but  $fT_3$  showed a 22% increase ( $U = 59$ ,  $z = -2.69$ ,  $p = 0.007$ ), and the growth factors IGF-I and IGFBP-3 were elevated by 10% (not significant; fig. 1b).

#### Hormone Levels: Relations to Age

DHEA-S levels tended to increase with age in both groups ( $r = +0.33$ ,  $p = 0.03$ ,  $n = 41$ ; fig. 2). Higher levels were maintained in younger and older CD children [ $<14$  years, 6 CON/20 CD, 609 (SD 594) vs. 1,187 (SD 662);

$>14$  years, 6 CON/8 CD, 1,200 (SD 604) vs. 1,824 ng/ml (SD 640);  $U = 32-11$ ,  $z = -1.7$ ,  $p = 0.09$ ]. In contrast, ACTH secretion did *not* correlate with age in either group, but like DHEA-S, higher levels were maintained in the younger and older patients [CD: 50 (SD 55) to 43 (SD 22) vs. CON: 6.5 (SD 6) to 12 (SD 17) pg/ml;  $U = 1-5$ ,  $z = -3.2$  to  $-2.2$ ,  $p = 0.001-0.03$ ]. In controls, CS levels tended to correlate with age ( $r = +0.58$ ,  $p = 0.05$ ).

Levels of  $fT_3$  were unrelated to age in either group. The higher levels in the CD group were restricted to the younger subjects [ $<14$  years, 6 CON/17 CD, 3.3 (SD 0.8) vs. 4.5 (SD 0.7);  $>14$  years, 5 CON/8 CD, 4.0 (SD 0.9) vs. 4.4 (SD 0.5) pg/ml;  $U = 17$ ,  $z = -2.6$ ,  $p = 0.009$ ]. IGF-I levels (not IGFBP-3) increased with age in both groups ( $r = +0.45$ ,  $p = 0.004$ ,  $n = 41$ ), and, like  $fT_3$ , levels tended to be higher in the younger patients [ $<14$  years, 6 CON/20 CD, 153 (SD 122) vs. 256 (SD 130) ng/ml;  $U = 32$ ,  $z = -1.7$ ,  $p = 0.09$ ]. IGFBP-3 showed a similar trend in the young CD patients [3.3 (SD 1.0) vs. 4.1 (SD 1.1) mg/ml; MW  $U = 32.5$ ,  $z = -1.7$ ,  $p = 0.09$ ].

PRL and  $E_2$  levels increased with age more in the CD than the control group [PRL:  $r = +0.45$  (vs.  $+0.24$ ),  $p = 0.003$ ;  $E_2$ :  $r = +0.79$  (vs.  $+0.21$ ),  $p < 0.0001$ ], attaining levels that tended to be higher in older CD versus CON subjects ( $E_2$ :  $U = 9$ ,  $z = -1.94$ ,  $p = 0.05$ ; PRL:  $U = 4$ ,  $z = -2.58$ ,  $p < 0.01$ ).

#### *Hormone Levels: Relations to Physical and Sexual Maturity*

There were no group differences in sexual maturity, but in the 6 CD and 4 CON children with accelerated maturity, levels of LH, FSH, Te,  $E_2$ , IGF-I were increased and CS decreased, as expected. The absence of correlations for these hormones with measures of physique in the CON group contrasted with clear relationships in the CD group that can only partially be accounted for by sample size. Thus LH, Te and  $E_2$  correlated strongly with all five measures ( $r = +0.59$ – $0.80$ ,  $p = 0.001$ – $0.00001$ ). Less marked were correlations for each measure with DHEA-S [ $r = +0.35$  ( $p = 0.06$ , legs) to  $+0.56$  ( $p = 0.002$ , chest); fig. 2] and IGF-I ( $r = +0.38$ – $0.50$ ,  $p < 0.036$ – $0.1$ ).

#### *Hormone Levels: Relations to Behaviour*

Increasing sum scores of the Conners rating (table 1) correlated with increasing levels of ACTH ( $r = +0.48$ ,  $p < 0.005$ ,  $n = 33$ ; fig. 2) and  $fT_3$  ( $r = +0.41$ ,  $p = 0.01$ ,  $n = 36$ ) with a trend relationship to DHEA-S levels ( $r = +0.28$ ,  $p = 0.08$ ,  $n = 39$ ). Correlations with symptom severity focused on DHEA-S, ACTH and  $fT_3$ . The following pattern emerged with  $p < 0.01$ . ACTH was positively related to restless, impulsive and aggressive behaviour,  $fT_3$  with fidgeting, and DHEA-S levels were associated with disturbing others (fig. 2). Unique to the question 'does the child cry easily?' was a negative relationship with LH, Te and  $E_2$  ( $r = -0.35$  to  $-0.44$ ,  $p = 0.008$ – $0.03$ ) and no relationship with other hormones.

#### *Relationships between Circulating Hormone Levels*

Normal positive correlations were seen in both groups between hormones of the pituitary-gonadal axis (e.g. LH, FSH, Te,  $E_2$ , PRL). These also correlated with the growth factors IGF-I and IGFBP-3 in both groups. Notable on the pituitary-adrenal axis was (1) the absence of a relationship between ACTH and CS; (2) that DHEA-S correlated only with  $E_2$  (both groups) and, in controls only, with IGF-I, and (3) the growth factors and  $fT_3$  (not TSH or  $fT_4$ ) were inter-related in both groups. The CD group alone showed a relationship of  $fT_3$  with IGFBP-3 and a negative association of Te with TSH.

In summary, it is notable that where hormone levels differed between groups, there were unusual differences in the inter-hormone relationships. First, ACTH correlated with LH, FSH, PRL and Te only in the CD group. Second, the growth factors showed mixed relationships (with DHEA-S and PRL in controls only, or with  $fT_3$  and IGF-I in the CD group only). Third, DHEA-S was associated with IGF-I in the controls but not in the CD group.

## **Discussion**

This sample of CD children was impulsive, restless and disturbed others; they tended to have smaller anthropometric measures but show similar levels of sexual development to normal age-matched children. The CD group showed increased levels of ACTH, DHEA-S, and the younger subjects small increases in  $fT_3$ , IGF-I and IGFBP-3. These hormone levels correlated with several indices of physical stature and psychopathology. But, gonadal hormone levels did not differ between groups and were not associated with signs of aggression. We discuss these findings in terms of the pituitary-adrenal, gonadal and growth hormone axes.

Increased ACTH levels were related to some ADHD-like features (restless, impulsive and some externalising behaviour): this parallels measures in adults with a potential for aggressive behaviour [20, 21]. The increased levels of PRL and ACTH in CD subjects could reflect low serotonin metabolism and thus reduced behavioural inhibition: negative correlations were reported for CSF serotonin metabolites of young persons with disruptive behaviour [22]. The absence of differences in CS levels is consistent with a study of ADHD children with/without comorbid CD [8] and the absence of a correlation of increased CS with aggression in disruptive adolescents after a serotonin-releasing challenge with fenfluramine [23].

A change in ACTH levels without a rise in CS is not unusual. For example, voluntarily waking earlier than usual is preceded by increases in ACTH 1 h before, without the CS changes that would accompany being awoken early [24]. ACTH levels rise in anticipation of having to cope with stress (e.g. wakefulness), CS levels reflect more a response to stress and activity. Here we find it telling that (1) ACTH levels were associated with increased activity; (2) associated PRL changes likely reflected decreased serotonin metabolism, associated with increased motor output [25] and reported from children with disruptive behaviour [22], and (3) increases in CS are enhanced by serotonin release, which seems unlikely here [25].

Irritability and readiness to respond violently are reported from male adolescents [26] and adults [27] with high levels of Te. However, as with other studies of aggressive children [28, 29], we found that neither gonadal steroid levels nor the timing of sexual maturity was unusual in CD subjects. On the question of immaturity, it is interesting that CD children were rated highly for 'crying', perhaps reflecting emotional immaturity, and this feature correlated with decreased levels of LH, Te and E<sub>2</sub>. Signs of delayed maturation and labile affect were described for teenagers with ADHD comorbid with personality disorders [30].

The unexpectedly high DHEA-S levels in pre- and postpubertal CD children contrast with a report of no differences in serum DHEA in prepubertal children hospitalised for aggressive behaviour [28], but parallel a report of nearly twofold increases in prepubertal 8- to 12-year-old CD children [29]. Levels of DHEA-S and delta-5 androgens increase from about 6 to 8 years through puberty, reflecting maturation of the adrenal cortex, and then decrease in young adulthood. An increase, often independent of CS or PRL can be associated with hyperprolactinaemia [31]. Thus, in view of a tendency for increased PRL levels in CD subjects, future studies should examine if changes in dopamine or serotonin activity, important in the control of PRL secretion, could underlie the endocrine changes.

What might an increase in DHEA-S in CD subjects reflect? Increases have been associated with self-confidence, an ebullient personality and extraverted aggression [32-34]. DHEA-S levels were also found to be high in male adolescents with schizophrenia [35]. Young male schizophrenic and CD patients share some early risk factors albeit for separate pathways of psychopathological development (e.g. dysfunctional families enhancing internalising and externalising features [3]). As laboratory studies of development have shown DHEA-S enhances neuronal survival and protects against neurotoxic insults [36, 37], we predict that increased DHEA-S secretion may delay normal neurodevelopmental pruning processes.

Levels of IGF-I and IGFBP-3, reliable indicators of growth hormone function, increase from 5 years through puberty and then decline during adult life. Increases in the IGF-I/IGFBP-3 ratio are seen in growth hormone deficiency [38] and may be associated with cognitive and mood changes in adults [39]. Our data confirm positive correlations in both groups for growth factors, age, sexual maturity ratings and LH secretion. Levels of both factors and IGF ratios (CON 67.3 vs. CD 66.3) showed no signs of deficiency. Yet, there was a trend for increased IGF-I

levels in the younger CD subjects and for correlations with physique (like DHEA-S, fig. 2). IGFBP-3 levels increased normally with age in controls, but in CD subjects, levels were stable with age and correlated with FT<sub>3</sub> levels. Elsewhere, differences in stature were not evident for patients with CD or related disorders [40].

Increases in FT<sub>3</sub> levels by a third in young CD subjects is not inconsistent with a reported incidence of abnormal TSH, FT<sub>3</sub> or FT<sub>4</sub> levels in 35% of 193 adolescent psychiatric referrals [41]. The short stature and delayed maturity noted resembles very mild hypothyroidism. A degree of hyper- or hypothyroidism often accompanies other medical conditions, and along with a euthyroid clinical status is not an indicator for intervention. Our data do not support a background of thyroid resistance in young persons with CD [12], even though associations of FT<sub>3</sub> with restlessness and impulsive behaviour are similar to data [12] of normal subjects.

In conclusion, these preliminary results show minor abnormal changes in adrenal-pituitary activity, indicative of a down-regulation and evident at the onset of adolescence in children with CD. Of these changes, perhaps only the putative neurotropic protective effect of high DHEA-S levels may have long-term consequences. These effects may include an alteration of the sensitivity of monoaminergic projection areas, where abnormal function has been related to conditions such as substance abuse, a vulnerability for which CD is prognostic.

### Acknowledgments

We are very grateful to Ms. U. Augustiniak and Ms. S. Tappeser for the hormone analysis, to Dr. W. Strahl for the recruitment of the control children and to Dr. Mujakschin, Institute for Applied Physics, Nizhny Novgorod, for help with the data analysis. T.N.D. received a grant from the German Academic Exchange Service (DAAD).

## References

1. Lahey BB, McBurnett K, Loeber R, et al: Psychopathology of conduct disorder: In Sholevar GP (ed): *Conduct Disorders in Children and Adolescents: Assessments and Interventions*. Washington, American Psychiatric Press, 1995.
2. Kratzer L, Hodgkins S: Adult outcomes of child conduct problems: A cohort study. *J Abnorm Child Psychol* 1997;25:65-81.
3. Bernstein DP, Cohen P, Skodol A, et al: Childhood antecedents of adolescent personality disorders. *Am J Psychiatry* 1996;153:907-913.
4. Lynskey MT, Fergusson DM: Childhood conduct problems, attention deficit behaviors and adolescent alcohol, tobacco and illicit drug use. *J Abnorm Child Psychol* 1995;23:281-302.
5. Taylor EA, Chadwick O, Heptinstall E, et al: Hyperactivity and conduct problems as risk factors for adolescent development. *J Am Acad Child Adolesc Psychiatry* 1996;35:1213-1226.
6. Gispen-de Wied C, Jansen LMC, Wynne HJ, et al: Differential effects of hydrocortisone and dexamethasone on cortisol suppression in a child psychiatric population. *Psychoneuroendocrinology* 1998;23:295-305.
7. Walker JL, Lahey BB, Russo MF, et al: Anxiety, inhibition and conduct disorder in children. I. Relations to social impairment. *J Am Acad Child Adolesc Psychiatry* 1991;30:187-191.
8. Schulz KP, Halperin JM, Newcorn JH, et al: Plasma cortisol and aggression in boys with ADHD. *J Am Acad Child Adolesc Psychiatry* 1997;36:605-609.
9. Mattsson A, Schalling D, Ohwess D, et al: Plasma testosterone, aggressive behavior and personality dimensions in young male delinquents. *J Am Acad Child Adolesc Psychiatry* 1980;19:476-490.
10. Scerbo AS, Kolko DJ: Salivary testosterone and cortisol in disruptive children: Relationship to aggressive, hyperactive and internalizing behaviors. *J Am Acad Child Adolesc Psychiatry* 1994;33:1174-1184.
11. Oades RD: Frontal, temporal and lateralized brain function in children with attention-deficit hyperactivity-disorder (ADHD): A psychophysiological and neuropsychological viewpoint on development. *Behav Brain Res* 1998;94:83-95.
12. Hauser P, Soler R, Brucker-Davis F, et al: Thyroid hormones correlate with symptoms of hyperactivity but not inattention in attention-deficit hyperactivity disorder. *Psychoneuroendocrinology* 1997;22:107-114.
13. Eila J, Gulotta C, Rose SR, et al: Thyroid function and attention-deficit hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 1994;33:169-172.
14. Kretschmer E: *Körperbau und Charakter*. Heidelberg, Springer-Verlag, 1921.
15. Saugstad LP: The maturational theory of brain development and cerebral excitability in the multifactorially inherited manic-depressive psychosis and schizophrenia. *Int J Psychophysiol* 1994;18:189-203.
16. Goyette CH, Conners CK, Ulrich RF: Normative data on revised Conners parent and teacher rating scale. *J Abnorm Child Psychology* 1978;6:221-236.
17. Achenbach TL: *Manual for the Child Behavior Inventory*. Burlington, University of Vermont, 1991.
18. Tanner JM: *Fetus into man: Physical growth from conception to maturity*. Cambridge, Harvard University Press, 1978.
19. Prader A, Largo RH, Molinari L, et al: Physical growth of Swiss children from birth to 20 years of age. First Zürich longitudinal study of growth and development. *Helv Paediatr Acta* 1989;52(suppl):1-125.
20. Marti-Carbonell MA, Darba S, Gerri A, et al: Hormones and aggression. *Arch Neurobiol* 1992;55:162-174.
21. Virkkunen M, Linicola M: Brain serotonin, type II alcoholism and impulsive violence. *J Stud Alcohol* 1993;11(suppl):163-169.
22. Kraesi MJ, Hibbs ED, Zaha TP, et al: A 2-year prospective follow-up study of children and adolescents with disruptive behavior disorders. *Arch Gen Psychiatry* 1992;49:429-435.
23. Stoff DM, Pruskiempo AP, Yeung J, et al: Neuroendocrine responses to challenge with  $\alpha$ -flumethazine and aggression in disruptive behavior disorders of children and adolescents. *Psychiatry Res* 1992;43:263-276.
24. Born J, Hansen K, Marshall, et al: Timing the end of nocturnal sleep. *Nature* 1999;397:29.
25. Lucki I: The spectrum of behavior influenced by serotonin. *Biol Psychiatry* 1998;44:151-162.
26. Ohwess D, Mattsson A, Schalling D, et al: Circulating testosterone levels and aggression in adolescent males: A causal analysis. *Psychosom Med* 1988;50:261-272.
27. Gerra G, Avanzini P, Zaimovic A, et al: Neurotransmitter and endocrine modulation of aggressive behaviour and its components in normal humans. *Behav Brain Res* 1997;81:19-24.
28. Constantino JN, Gross D, Saenger P, et al: Testosterone and aggression in children. *J Am Acad Child Adolesc Psychiatry* 1993;32:1217-1222.
29. Van Goozen SHM, Matthys W, Cohen-Kettenis PT, et al: Adrenal androgens and aggression in conduct disorder prepubertal boys and normal controls. *Biol Psychiatry* 1998;43:156-158.
30. Dmitrieva TN: Deviant behavior in children and adolescents with psychopathological features of conduct disturbance. Unpublished thesis, National Scientific Centre for Psychiatry and Narcology, Moscow, 1996.
31. Giusti G, Bassi F, Forti G, et al: Effects of prolactin on androgen secretion by the human adrenal cortex: In Robyn C, Harteis M (ed): *Progress in Prolactin Physiology and Pathology*. Amsterdam, Elsevier, 1978, pp 293-303.
32. Strauss EB, Sands DE, Robinson AM, et al: Use of dehydroepiandrosterone in psychiatric treatment. *Br Med J* 1992;3:64.
33. Sands DE: Further studies on endocrine treatment in adolescence and early adult life. *J Ment Sci* 1954;100:211-219.
34. Hermida RC, Hallberg F, del Pozo F: Chronobiologic pattern discrimination of plasma hormones, notably DHEA-S and TSH, classified an expansive personality. *Chronobiology* 1985;12:105-135.
35. Oades RD, Schepker R: Serum gonadal steroid hormones in young schizophrenic patients. *Psychoneuroendocrinology* 1994;19:373-385.
36. Bologna L, Sharma J, Roberts E: Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures. *J Neurosci Res* 1987;17:225-234.
37. Kimoaides VG, Khatibi NH, Svendsen CN, et al: Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against amino-acid-induced neurotoxicity. *Proc Natl Acad Sci USA* 1998;95:1852-1857.
38. Benbasat CA, Maki KC, Unterman TG: Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: Relationships to insulin, glucose, IGF and dehydroepiandrosterone sulfate levels and anthropometric measures. *J Clin Endocrinol Metab* 1997;82:1484-1491.
39. Deijen JB, de Boer H, Biok GH, et al: Cognitive impairments and mood disturbances in growth hormone deficient men. *Psychoneuroendocrinology* 1996;21:313-322.
40. Spencer TJ, Biederman J, Harding M, et al: Growth deficits in ADHD children revisited: Evidence for disorder-associated growth delays? *J Am Acad Child Adolesc Psychiatry* 1996;35:1460-1469.
41. Leo RJ, Batterman-Faunce JM, Pickhardt D, et al: Utility of thyroid function screening in adolescent psychiatric inpatients. *J Am Acad Child Adolesc Psychiatry* 1997;36:103-111.